A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium.

Trial Profile

A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Hyperlipidaemia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Feb 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 27 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top